Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNETs) based on the tumor size and hormonal production

Journal of Gastroenterology

Volumn 47, Issue 6, 2012, Pages 678-685

  Tsutsumi, Kosuke ^a   Ohtsuka, Takao ^a   Mori, Yasuhisa ^a   Fujino, Minoru ^a   Yasui, Takaharu ^a   Aishima, Shinichi ^a   Takahata, Shunichi ^a   Nakamura, Masafumi ^a   Ito, Tetsuhide ^a   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Gastrinoma; Lymph node metastasis; Non gastrinoma; Pancreatic neuroendocrine tumor (PNET)

Indexed keywords

GASTRIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTRINOMA; GLUCAGONOMA; HORMONE SYNTHESIS; HUMAN; INSULINOMA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PANCREAS RESECTION; PANCREATIC NEUROENDOCRINE TUMOR; POST TREATMENT SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SOMATOSTATINOMA; SURVIVAL RATE; TREATMENT INDICATION; TUMOR VOLUME;

ADULT; AGED; FEMALE; GASTRINOMA; HORMONES; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATECTOMY; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84865132028     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-012-0540-0     Document Type: Article

References (31)

1. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1766-73. (Pubitemid 40995093)
2. Jarufe NP, Coldham C, Orug T, Mayer AD, Mirza DF, Buckels JA, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg. 2005;22:157-62. (Pubitemid 41330835)
3. Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10:327-31. (Pubitemid 43303823)
4. Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, et al. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247:490-500.
5. Kloppel G, Couvelard A, Perren A, Komminoth P, McNicol AM, Nilsson O, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendo-crine tumors and their prognostic stratification. Neuroendocri-nology. 2009;90:162-6.
6. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Vir-chows Arch. 2006;449:395-401. (Pubitemid 44451313)
7. Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, et al. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors, 3rd ed. J Natl Compr Cancer Netw. 2009;7:712-47.
8. Klimstra DS, Arnold R, Capella C, Hruban RH, Kloppel G, Komminoth P, et al. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND, editors. WHO classification of tumours of the digestive system. Lyon: IARC Press; 2010. p. 322-6.
9. Soga J, Yakuwa Y. The gastrinoma/Zollinger-Ellison syndrome: statistical evaluation of a Japanese series of 359 cases. J Hepa-tobiliary Pancreat Surg. 1998;5:77-85. (Pubitemid 128662561)
10. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469-92.
11. Imamura M, Kanda M, Takahashi K, Shimada Y, Miyahara T, Wagata T, et al. Clinicopathological characteristics of duodenal microgastrinomas. World J Surg. 1992;16:703-9.
12. Pipeleers-Marichal M, Donow C, Heitz PU, Kloppel G. Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg. 1993;17:481-8. (Pubitemid 23228401)
13. Japan Pancreas Society. General Rules for the Study of Pancreatic Cancer. 6th ed. Kanehara: Tokyo; 2009.
14. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: A fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-77. (Pubitemid 23118304)
15. Akobeng AK. Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr. 2007;96:644-7. (Pubitemid 46653167)
16. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg. 2003;197:29-37. (Pubitemid 36759176)
17. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: A 15-year single center prospective study. Surgery. 2003;133:375-82. (Pubitemid 36515325)
18. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003;134:1057-63.
19. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241: 776-83.
20. Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, et al. Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Ann Oncol. 2008;19:903-8. (Pubitemid 351627305)
21. Nomura N, Fujii T, Kanazumi N, Takeda S, Nomoto S, Kasuya H, et al. Nonfunctioning neuroendocrine pancreatic tumors: our experience and management. J Hepatobiliary Pancreat Surg. 2009;16:639-47.
22. Ikenaga N, Yamaguchi K, Konomi H, Fujii K, Sugitani A, Tanaka M. A minute nonfunctioning islet cell tumor demonstrating malignant features. J Hepatobiliary Pancreat Surg. 2005;12:84-7. (Pubitemid 40378847)
23. Gibril F, Venzon DJ, Ojeaburu JV, Bashir S, Jensen RT. Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab. 2001;86:5282-93. (Pubitemid 33070249)
24. Imamura M, Komoto I, Ota S. Changing treatment strategy for gastrinoma in patients with Zollinger-Ellison syndrome. World J Surg. 2006;30:1-11. (Pubitemid 43081606)
25. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al. Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology. 2006;84:183-8. (Pubitemid 46361052)
26. Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. Improved contemporary surgical management of insulinomas: A 25-year experience at the Massachusetts General Hospital. Ann Surg. 2008;247:165-72.
27. Ito T, Sasano H, Tanaka M, Osamura RY, Sasaki I, Kimura W, et al. Epidemiological study of gastroenteropancreatic neuroen-docrine tumors in Japan. J Gastroenterol. 2010;45:234-43.
28. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1-and 123I-Tyr3-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-31. (Pubitemid 23284773)
29. Chang F, Vu C, Chandra A, Meenan J, Herbert A. Endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic neuroendocrine tumours: cytomorphological and immunocyto-chemical evaluation. Cytopathology. 2006;17:10-7.
30. Chatzipantelis P, Konstantinou P, Kaklamanos M, Apostolou G, Salla C. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: A study by endoscopic ultrasound-guided fine-needle aspiration cytology. Cancer Cytopathol. 2009;117:211-6.
31. Imamura M, Takahashi K, Adachi H, Minematsu S, Shimada Y, Naito M, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. Ann Surg. 1987;205:230-9. (Pubitemid 17037044)